The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADVL1315: A phase 1 study of the VEGF receptor tyrosine kinase inhibitor axitinib (INLYTA, IND# 123101) in children with recurrent or refractory solid tumors—A Children's Oncology Group study.
 
James I. Geller
No Relationships to Disclose
 
Elizabeth Fox
No Relationships to Disclose
 
Brian Turpin
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Charles G. Minard
No Relationships to Disclose
 
Stuart Goldstein
Stock and Other Ownership Interests - Hemametrics
Consulting or Advisory Role - Akebia Therapeutics; AM Pharma; Astute; Baxter; Bellco; La Jolla Pharma; Otsuka
Speakers' Bureau - Baxter
Research Funding - Baxter
 
Brenda Weigel
Travel, Accommodations, Expenses - Genentech; Lilly/ImClone; Nektar; Roche/Genentech; Roche/Genentech